Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) Operating Expenses (2016 - 2025)

Marimed (MRMD) has disclosed Operating Expenses for 15 consecutive years, with $14.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses fell 4.17% to $14.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $59.8 million, a 1.58% decrease, with the full-year FY2024 number at $60.0 million, up 16.34% from a year prior.
  • Operating Expenses was $14.8 million for Q3 2025 at Marimed, down from $14.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $16.0 million in Q1 2025 to a low of $6.1 million in Q1 2021.
  • A 5-year average of $12.6 million and a median of $13.5 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: soared 297.64% in 2021, then dropped 10.95% in 2022.
  • Marimed's Operating Expenses stood at $14.3 million in 2021, then fell by 10.95% to $12.7 million in 2022, then increased by 17.16% to $14.9 million in 2023, then dropped by 5.31% to $14.1 million in 2024, then rose by 4.81% to $14.8 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Operating Expenses are $14.8 million (Q3 2025), $14.9 million (Q2 2025), and $16.0 million (Q1 2025).